GlassScriptPhysician profile
Ashutosh H Patel
NPI 1588735575
$4,474.34
in general payments reported to CMS, 2019-2025
20 companies · $851 in 2025
The $851 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $512 · 2021: $225 · 2022: $636 · 2023: $734 · 2024: $388 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,154.54 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $843.98 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.48 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $391.55 | 2019-2023 | Shingrix |
| Amgen INC. | $234.54 | 2019-2025 | Otezla, Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $198.68 | 2025 | Uptravi, Opsumit |
| Organogenesis INC. | $143.80 | 2022-2023 | Puraply |
| Allergan, INC. | $127.61 | 2019 | |
| Sumitomo Pharma America, INC. | $125.00 | 2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $122.58 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $116.54 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.33 | 2025 | Glassia |
| E.R. Squibb & Sons, L.L.C. | $107.92 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $95.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $63.09 | 2020-2023 | Verquvo, Belsomra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $55.34 | 2020-2021 | |
| Abbvie INC. | $25.62 | 2021 | |
| Optos, INC. | $24.21 | 2021 | |
| Exact Sciences Corporation | $16.92 | 2024 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashutosh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.